CN107072977A - Nep抑制剂药物组合及其应用 - Google Patents

Nep抑制剂药物组合及其应用 Download PDF

Info

Publication number
CN107072977A
CN107072977A CN201580049644.2A CN201580049644A CN107072977A CN 107072977 A CN107072977 A CN 107072977A CN 201580049644 A CN201580049644 A CN 201580049644A CN 107072977 A CN107072977 A CN 107072977A
Authority
CN
China
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
compound
acceptable salt
hypertension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580049644.2A
Other languages
English (en)
Other versions
CN107072977B (zh
Inventor
包如迪
王娟娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN107072977A publication Critical patent/CN107072977A/zh
Application granted granted Critical
Publication of CN107072977B publication Critical patent/CN107072977B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

一种包含中性内肽酶抑制剂的药物组合物及其在制备治疗或预防与中性内肽酶有关的疾病的药物中的用途。所述组合物包括(i)(9R，11S)‑11‑([1,1'‑联苯]‑4‑基甲基)‑2,6,9‑三甲基‑4,8,13‑三氧代‑3,5,7‑三氧杂‑12‑氮杂十六烷‑16‑酸(化合物1)或其可药用盐，和/或(ii)血管紧张素Ⅱ拮抗剂或其可药用盐，和/或(iii)血管紧张素转化酶抑制剂，和(ⅳ)可药用载体。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201580049644.2A 2014-12-03 2015-11-26 Nep抑制剂药物组合及其应用 Active CN107072977B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014107293304 2014-12-03
CN201410729330 2014-12-03
PCT/CN2015/095626 WO2016086790A1 (zh) 2014-12-03 2015-11-26 Nep抑制剂药物组合及其应用

Publications (2)

Publication Number Publication Date
CN107072977A true CN107072977A (zh) 2017-08-18
CN107072977B CN107072977B (zh) 2019-11-22

Family

ID=56090999

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580049644.2A Active CN107072977B (zh) 2014-12-03 2015-11-26 Nep抑制剂药物组合及其应用

Country Status (3)

Country Link
CN (1) CN107072977B (zh)
TW (1) TW201620511A (zh)
WO (1) WO2016086790A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101119718A (zh) * 2005-02-18 2008-02-06 索尔瓦药物有限公司 包含nep-抑制剂，内源性内皮素产生系统抑制剂和利尿剂的药物组合物
CN104230865A (zh) * 2013-06-13 2014-12-24 上海翰森生物医药科技有限公司 联芳基取代的4-氨基丁酸衍生物及其制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101119718A (zh) * 2005-02-18 2008-02-06 索尔瓦药物有限公司 包含nep-抑制剂，内源性内皮素产生系统抑制剂和利尿剂的药物组合物
CN104230865A (zh) * 2013-06-13 2014-12-24 上海翰森生物医药科技有限公司 联芳基取代的4-氨基丁酸衍生物及其制备方法和用途

Also Published As

Publication number Publication date
TW201620511A (zh) 2016-06-16
CN107072977B (zh) 2019-11-22
WO2016086790A1 (zh) 2016-06-09

Similar Documents

Publication Publication Date Title
JP2014098016A (ja) 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用
TW200831078A (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
AU2004283047B2 (en) Pharmaceutical composition comprising a selective I1 imidazoline receptor agonist and an angiotensin II receptor blocker
CN101926793B (zh) 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
WO2019130277A1 (en) Pharmaceutical formulations of azilsartan medoxomil
WO2008148359A1 (fr) Utilisations thérapeutiques de dérivés d'acide imidazol-5-carboxylique
CN107072977A (zh) Nep抑制剂药物组合及其应用
JP2016505628A (ja) ２−アミノエタンスルホン酸との組み合わせ
WO2022036506A1 (zh) Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途
CN115243774B (zh) 含氨氯地平、氯噻酮和阿米洛利的药物组合物
CN113226374B (zh) 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物
CN101987200B (zh) 含有降压肽和醛固酮受体拮抗剂的治疗高血压的复方药物
WO2011126327A2 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
CN103037861A (zh) 黄嘌呤氧化酶抑制剂与血管紧张素ii受体拮抗剂的组合及其用途
TWI484955B (zh) 治療包括人類之哺乳動物中第２型糖尿病的醫藥組成物
BR112014007876B1 (pt) Forma de dosagem, composição, processo para preparação de uma composição, uso de uma composição
EP4358959A1 (en) Methods of using aldosterone synthase inhibitors
WO2022123592A1 (en) Stable pharmaceutical composition of azilsartan medoxomil or pharmaceutical acceptable salt and processes for preparing thereof
TWI494313B (zh) 治療包括人類之哺乳動物中第２型糖尿病的醫藥組成物
WO2011009360A1 (zh) 治疗哺乳动物包括人2型糖尿病的药物组合物
CN103467405B (zh) 一类四氮唑羧酸类化合物、其制备方法和用途
RU2203051C1 (ru) Лекарственное средство для лечения сердечно-сосудистых заболеваний
KR20210152943A (ko) 암로디핀, 로사르탄 및 클로르탈리돈을 단층정에 포함하는 심혈관계 질환의 예방 또는 치료용 약제학적 복합제제
TWI462925B (zh) 治療２型糖尿病的藥物組合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant